Organization and Business (Details Narrative) - USD ($)		1 Months Ended		4 Months Ended	10 Months Ended	12 Months Ended
	Feb. 18, 2015	Feb. 28, 2015	Mar. 31, 2014	Nov. 30, 2015	Mar. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Aug. 31, 2015	Jun. 30, 2015	Dec. 31, 2013	Aug. 10, 2012
Percentage of pier issued and outstanding share acquire											100.00%
Net losses						$ 5,961,892	$ 2,707,535
Negative operating cash flows						1,296,100	885,869
Stockholders' deficiency						$ 2,862,209	$ 2,200,400			$ 4,188,424
Percentage of dividend on convertible preferred stock						1.50%	1.50%
Invested in preferred stock	$ 579,500
Accrued interest						$ 61,388	$ 4,093
Advanced amount						40,000	$ 75,000
Chairman and Chief Executive Officer [Member]
Due to officers									$ 40,000
President And Chief Executive Officer [Member]
Due to officers								$ 250,000
Chief Executive Officer [Member]
Advanced amount						52,600
Chief Scientific Officer [Member]
Advanced amount						52,600
Chief Executive Officer And Chief Scientific Officer [Member] | Secured Short Term Promissory Notes Payable [Member]
Advanced amount						105,200
Private Placement [Member]
Sale of common stock and warrants units				56,809,802
Proceeds from common stock and warrants				$ 1,194,710		194,635
Repaid the short term loan				40,000
Accrued interest				$ 877
Private Placement [Member] | Series G 1.5% Convertible Preferred Stock [Member] | Chairman and Chief Executive Officer [Member]
Invested in preferred stock			$ 250,000
Private Placement [Member] | Series G 1.5% Convertible Preferred Stock [Member] | March And April 2014 [Member]
Sale of preferred stock							928.5
Percentage of dividend on convertible preferred stock							1.50%
Invested in preferred stock							$ 928,500
Chairman and Chief Executive Officer [Member]
Short term loans advanced to the company					$ 150,000
Investors [Member]
Short-term convertible notes and warrants principal amount		$ 210,000
Investors [Member] | November And December 2014 [Member]
Short-term convertible notes and warrants principal amount						369,500
March 2016 [Member]
Direct costs in clinical trial						$ 750,000